Immunoglobulin A Nephropathy research hub

A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy

This study looks at a new drug, Sparsentan, for people with kidney disease called IgA Nephropathy. It aims to see if the drug is safe and helpful in protecting the kidneys, both for newly diagnosed patients and those who have had a kidney transplant.

A FIRST-IN-HUMAN PHASE I TRIAL OF OX118 IN HEALTHY VOLUNTEERS

This early-stage study is looking at a new medicine called OX118 for the very first time in people. It aims to see if it's safe and how it works in healthy volunteers, meaning people who don't have any immune system diseases.

A study to investigate how different tablet types of balinatunfib and food will influence the absorption of balinatunfib in blood in healthy adult participants

This study looks at how a new medicine, balinatunfib, is absorbed into the blood when taken in different tablet forms and with or without food. It involves healthy adults and aims to understand the best way for the body to take in the medicine, which is being developed for immune system diseases.

A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis

This study is testing a new medicine called Duvakitug for people with moderate to severe ulcerative colitis. It aims to see if Duvakitug can help keep symptoms in remission (controlled) and improve quality of life compared to a dummy medicine.

A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease

This study is looking at a new medicine called duvakitug for people with moderate to severe Crohn's disease. Researchers want to see if it helps keep the disease under control and is safe to use. It's a phase 3 study, meaning many people will take part.

First-in-human study of SAR445611 in healthy adult participants

Effect of SAR445611 on inflammatory responses following LPS challenge study in healthy participants